Klabin (OTCMKTS:KLBAY – Get Free Report) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks reports.
Klabin Trading Down 1.4%
Shares of Klabin stock opened at $7.54 on Thursday. The stock has a market cap of $23.53 billion, a P/E ratio of 44.64, a P/E/G ratio of 2.01 and a beta of 0.65. The company has a quick ratio of 1.37, a current ratio of 1.78 and a debt-to-equity ratio of 2.01. Klabin has a 12-month low of $6.34 and a 12-month high of $10.23. The business’s 50 day moving average is $6.98 and its 200-day moving average is $7.12.
Klabin (OTCMKTS:KLBAY – Get Free Report) last issued its earnings results on Wednesday, August 5th. The basic materials company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.02 billion. Klabin had a return on equity of 1.79% and a net margin of 1.26%. Equities research analysts predict that Klabin will post 0.25 earnings per share for the current fiscal year.
About Klabin
Klabin SA is a Brazilian integrated paper and pulp company that develops, manufactures and sells a range of forest products and packaging solutions. Founded by the Klabin family in 1899 and headquartered in São Paulo, the company’s activities span forestry management, pulp and paper manufacturing, containerboard and corrugated packaging production, and recycling operations. Klabin supplies both industrial and consumer-oriented paper and packaging products, including kraftliner, corrugating medium, cartonboard and specialty papers used across multiple end markets.
As an integrated forest products company, Klabin manages planted timberlands and brings raw material through its own supply chain into pulping and papermaking facilities.
Featured Stories
- Five stocks we like better than Klabin
- Lululemon’s Earnings Beat Hid a Bigger Problem for Its Turnaround Story
- MarketBeat Week in Review – 08/31 – 09/04
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
Receive News & Ratings for Klabin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Klabin and related companies with MarketBeat.com's FREE daily email newsletter.
